Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.89
Nov 20 • 3:59 PM ET Dollar change-0.27 Percentage change(-8.54%)
Aftermarket Close
2.91
Aftermarket • 7:39 PM ET Dollar change+0.02 Percentage change(0.69%)
Index
-
Market Cap
2.37M
Enterprise Value
28.54M
Income
-33.04M
Sales
0.45M
Book/sh
-31.42
Cash/sh
3.34
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
8
IPO
Feb 18, 2022
P/E
0.00
Forward P/E
-
PEG
-
P/S
5.26
P/B
-
P/C
0.86
P/FCF
-
EV/EBITDA
-
EV/Sales
63.42
Quick Ratio
1.43
Current Ratio
1.47
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
1057.82
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
83.59% 52.21%
Sales past 3/5Y
- -
EPS Y/Y TTM
100.78%
Sales Y/Y TTM
-63.63%
EPS Q/Q
97.57%
Sales Q/Q
-66.12%
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
7.40%
Inst Trans
-
ROA
-187.60%
ROE
-443.92%
ROIC
-286.91%
Gross Margin
73.81%
Oper. Margin
-1578.28%
Profit Margin
-7423.86%
SMA20
-34.68%
SMA50
-49.30%
SMA200
-96.50%
Trades
Shs Outstand
0.55M
Shs Float
-
52W High
1610.00 -99.82%
52W Low
2.76 4.71%
Volatility
10.24% 21.85%
ATR (14)
0.83
RSI (14)
38.01
Beta
2.67
Rel Volume
0.11
Avg Volume
407.05K
Volume
43,155
Perf Week
-9.97%
Perf Month
-28.96%
Perf Quarter
-55.95%
Perf Half Y
-76.69%
Perf YTD
-99.63%
Perf Year
-99.75%
Perf 3Y
-100.00%
Perf 5Y
-
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
3.16
Price
2.89
Change %
-8.54%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HRT FINANCIAL LP10% OwnerApr 21 '26Sale0.6949,71034,30033,649Apr 22 02:59 PM
HRT FINANCIAL LP10% OwnerApr 17 '26Buy0.7334,63625,284177,821Apr 21 03:41 PM
HRT FINANCIAL LP10% OwnerApr 20 '26Sale0.7594,46270,84683,359Apr 21 03:41 PM
HRT FINANCIAL LP10% OwnerApr 16 '26Sale0.7353,86739,323143,185Apr 21 03:41 PM
HRT FINANCIAL LP10% OwnerApr 15 '26Buy0.7692,55470,341197,052Apr 16 02:30 PM
HRT FINANCIAL LP10% OwnerApr 14 '26Buy0.7774,35057,250104,498Apr 16 02:30 PM
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.
Interim Chief Financial OfficerMs. Karina M. Fedasz
C.P.A.Mr. David Allan White C.A.
Global Head of Biologics OperationsMr. Andrew D. Skibo Ph.D.
Head of Business DevelopmentMr. Theodore Scott Yoho
Head of Science & DiscoveryDr. Ali I. Fattom Ph.D.